[1] TAJES M,RAMOS-FERNANDEZ E,WENGJIANGX,et al. The blood-brain barrier:structure,function and therapeutic approaches to cross it[J].Mol Membr Biol,2014,31(5):152-167.[2] HAWKINS R A,O’KANE R L,SIMPSON I A,etal. Structure of the blood-brain barrier and its role inthe transport of amino acids[J]. J Nutr,2006,136(1suppl):218S-226S.[3] CHOW B W,GU C. The molecular constituents ofthe blood-brain barrier[J]. Trends Neurosci,2015,38(10):598-608.[4] SWEENEY M D,AYYADURAI S,ZLOKOVIC BV. Pericytes of the neurovascular unit:Key functionsand signaling pathways[J]. Nat Neurosci,2016,19(6):771-783.[5] BELL R D,WINKLER E A,SAGARE A P,et al.Pericytes control key neurovascular functions andneuronal phenotype in the adult brain and duringbrain aging[J]. Neuron,2010,68(3):409-427.[6] HAYDON P G,CARMIGNOTO G. Astrocytecontrol of synaptic transmission and neurovascularcoupling[J]. Physiol Rev,2006,86(3):1009-1031.[7] BALLABH P,BRAUN A,NEDERGAARD M.The blood-brain barrier:an overview Structure,regulation,and clinical implications[J]. NeurobiolDis,2004,16(1):1-13.[8] 赵海君,钱易,崔毓桂,等. 紧密连接的结构与功能[J]. 国际生殖健康/计划生育杂志,2013,32(5):384-386.[9] 周丽华,徐武华. Tau蛋白靶向的阿尔茨海默病免疫治疗研究现状[J]. 中国神经精神疾病杂志,2017,43(2):126-128.[10] CARRANO A,HOOZEMANS J J,VAN DER VIESS M,et al. Neuroinflammation and blood-brainbarrier changes in capillary amyloid angiopathy[J].Neurodegener Dis,2012,10(1-4):329-331.[11] SENQILLO J D,WINKLER E A,WALKER C T,et al. Deficiency in mural vascular cells coincideswith blood-brain barrier disruption in Alzheimer’sdisease[J]. Brain Pathol,2013,23(3):303-310.[12] ALAFUZOFF I,ADOLFSSON R,ADOLFSSON R,et al. Blood-brain barrier in Alzheimer dementia andin non-demented elderly. An immunocytochemicalstudy[J]. Acta Neuropathol,1987,73(2):160-166.[13] TOMIMOTO H,AKIGUCHI I,SUENAGA T,etal. Alterations of the blood-brain barrier and glialcells in white-matter lesions in cerebrovascular andAlzheimer’s disease patients[J]. Stroke,1996,27(11):2069-2074.[14] SkILLBäCK T,DELSING L,SYNNERGREN J,etal. CSF/serum albumin ratio in dementias:a crosssectionalstudy on 1861 patients[J/OL]. NeurobiolAging,2017,59:1-9. https://doi.org/10.1016/j.neurobiolaging.2017.06.028.[15] MONTAGNE A,BARNES S R,SWEENEY M D,et al. Blood-brain barrier breakdown in the aginghuman hippocampus[J]. Neuron,2015,85(2):296-302.[16] VAN ASSEMA D M,LUBBERINK M,BAUER M,et al. Blood-brain barrier P-glycoprotein functionin Alzheimer’s disease[J]. Brain,2012,135(Pt 1):181-189.[17] 徐武华,常铉. 联合预防阿尔茨海默病与缺血性卒中的构想[J]. 医学与哲学,2014,35(7):76-77.[18] SWEENEY MD,SAGARE AP,ZLOKOVIC BV.Blood-brain barrier breakdown in Alzheimer diseaseand other neurodegenerative disorder[J]. Nat RevNeurol,2018,14(3):133-150.[19] BRUCKMANN S,BRENN A,GRUBE M,etal. Lack of P-glycoprotein Results in Impairmentof Removal of Beta--Amyloid and IncreasedIntraparenchymal Cerebral Amyloid Angiopathyafter Active Immunization in a Transgenic MouseModel of Alzheimer’s Disease[J]. Curr AlzheimerRes,2017,14(6):656-667.[20] LIU M,JEVTIC S,MARKHAM-COULTES K,etal. Investigating the efficacy of a combination Aβ-targeted treatment in a mouse model of Alzheimer’sdisease[J/OL]. Brain Research,2018,1678:138-145.https://doi.org/10.1016/j.brainres.2017.10.015.[21] RICCIARELLI R,FEDELE E. The amyloidCascade Hypothesis in Alzheimer’s disease:It’sTime to change Our Mind[J]. Curr Neuropharmacol,2017,15(6):926-935.[22] STORCK S E,MEISTER S,NAHRATH J,et al.Endothelial LRP1 transports amyloid-β(1-42)acrossthe blood-brain barrier[J]. J Clin Invest,2016,126(1):123-136.[23] SHIBATA M,YAMADA S,KUMAR S R,et al.Clearance of Alzheimer’s amyloid-ss(1-40)peptidefrom brain by LDL receptor-related protein-1 at theblood-brain barrier[J]. J Clin Invest,2000,106(12):1489-1499.[24] LAM F C,LIU R,LU P,et al. Beta-Amyloid effluxmediated by p-glycoprotein[J]. J Neurochem,2001,76(4):1121-1128.[25] CARRANO A,SNKHCHYAN H,KOOIJ G,et al.ATP-binding cassette transporters P-glycoproteinand breast cancer related protein are reduced incapillary cerebral amyloid angiopathy[J]. NeurobiolAging,2014,35(3):565-575.
[26] JEYNES B,PROVIAS J. Evidence for alteredLRP/RAGE expression in alzheimer lesionpathogenesis[J]. Curr Alzheimer Res,2008,5(5):432-437.[27] DEANE R,SINGH I,SAGARE A P,et al. AMultimodal RAGE-specific inhibitor reducesamyloid β-mediated brain disorder in a mouse modelof Alzheimer disease[J]. J Clin Invest,2012,122(4):1377-1392.[28] PETRUSHINA I,GHOCHIKYAN A,MKRTICHYAN M,et al. Mannan-Abeta28conjugate prevents Abeta-plaque deposition,but increases microhemorrhages in the brainsof vaccinated Tg2576(APPsw)mice[J/OL]. JNeuroinflammation,2008,5:42. https://doi.org/10.1186/1742-2094-5-42.[29] BIEN-LY N,BOSWELL C A,JEET S,et al. Lackof widespread BBB Disruption in Alzheimer’sDisease Models:Focus on Therapeutic Antibodies[J].Neuron,2015,88(2):289-297.